|
|
|
|
| LEADER |
02137nam a2200265 u 4500 |
| 001 |
EB002180654 |
| 003 |
EBX01000000000000001318141 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
231009 r ||| eng |
| 020 |
|
|
|a 0309696372
|
| 020 |
|
|
|a 9780309696371
|
| 100 |
1 |
|
|a Wizemann, Theresa M.
|
| 245 |
0 |
0 |
|a Inclusion of pregnant and lactating persons in clinical trials
|h Elektronische Ressource
|b proceedings of a workshop
|c Theresa Wizemann, Andrew March, and Carolyn Shore, rapporteurs ; Forum on Drug Discovery, Development, and Translation, Board on Health Sciences Policy, Health and Medicine Division
|
| 260 |
|
|
|a Washington, DC
|b National Academies Press
|c [2023], 2022
|
| 300 |
|
|
|a 1 PDF file (xviii, 127 pages)
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 700 |
1 |
|
|a March, Andrew
|e [rapporteur]
|
| 700 |
1 |
|
|a Shore, Carolyn
|e [rapporteur]
|
| 710 |
2 |
|
|a National Academies of Sciences, Engineering, and Medicine (U.S.)
|b Forum on Drug Discovery, Development, and Translation
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK587623
|3 Volltext
|
| 082 |
0 |
|
|a 140
|
| 520 |
|
|
|a Approximately 4 million pregnant people in the United States give birth annually, and 70 percent of these individuals take at least one prescription medication during their pregnancy. Yet, due to a number of historical, ethical, legal, scientific, and societal issues, pregnant and lactating persons are often excluded from clinical trials. As a result, pregnant and lactating persons are often taking drugs based on limited information about the benefits and risks to themselves and their developing or newborn baby. The National Academies Forum on Drug Discovery, Development, and Translation convened a workshop in June 2022 for stakeholders to examine the current state of evidence generation for drug products used by pregnant and lactating persons and discuss barriers and opportunities for including these populations in clinical trials. This publication summarizes the presentations and discussion of the workshop
|